TAVNEOS Drug Patent Profile

Which patents cover Tavneos, and what generic alternatives are available?

Tavneos is a drug marketed by Chemocentryx and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-one patent family members in thirty-nine countries.

The generic ingredient in TAVNEOS is avacopan. One supplier is listed for this compound. Additional details are available on the avacopan profile page.

DrugPatentWatch^® Generic Entry Outlook for Tavneos

Tavneos was eligible for patent challenges on October 7, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 27, 2039. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TAVNEOS

International Patents:	131
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TAVNEOS

Paragraph IV (Patent) Challenges for TAVNEOS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAVNEOS	Capsules	avacopan	10 mg	214487	3	2025-11-13

US Patents and Regulatory Information for TAVNEOS

TAVNEOS is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,951,214.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,603,356		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,445,515		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,951,214		Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,906,938		Y	Y

International Patents for TAVNEOS

When does loss-of-exclusivity occur for TAVNEOS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Moldova, Republic of

Morocco

New Zealand

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAVNEOS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020378397
Brazil	112022007489
Canada	3155542
Chile	2022001172

Supplementary Protection Certificates for TAVNEOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3508477	PA2022006,C3508477	Lithuania		PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111
2381778	202240009	Slovenia		PRODUCT NAME: AVACOPAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; NATIONAL AUTHORISATION NUMBER: EU/1/21/1605; DATE OF NATIONAL AUTHORISATION: 20220111; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2381778	LUC00258	Luxembourg		PRODUCT NAME: AVACOPAN ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119
2381778	SPC/GB22/014	United Kingdom		PRODUCT NAME: AVACOPAN (AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF); REGISTERED: UK EU/1/21/1605(FOR NI) 20220119; UK FURTHER MA ON IPSUM 20220119

Last updated: April 23, 2026

TAVNEOS (avacopan): Investment scenario and fundamentals analysis

TAVNEOS is the brand name for avacopan, an oral C5a receptor (C5aR) antagonist developed for ANCA-associated vasculitis (AAV). Commercial investment decisions for avacopan should be built around three pillars: (1) durability and breadth of approved use in AAV, (2) gross-to-net pressure from payer contracting and competitive positioning, and (3) the next-wave pipeline and life-cycle levers that can extend revenue beyond the current AAV franchise.

---

What is the product, mechanism, and labeled indication base?

Drug: TAVNEOS (avacopan)
Class: C5a receptor antagonist (C5aR)
Route: oral
Therapeutic area: ANCA-associated vasculitis (AAV)
Core premise: avacopan reduces inflammation driven by C5a signaling in AAV.

Labeled positioning inside AAV

Avacopan has regulatory clearance in AAV settings that differentiate it from corticosteroid-centric regimens. The investment relevance is twofold: steroid-sparing is a payer and provider-relevant endpoint, and it can support stronger adherence and formulary positioning if outcomes and tolerability are maintained in real-world use.

Key regulatory reference points

• FDA approval: 2021 (AAV indication)
• EMA approval: 2021 (AAV indication)

(See sources [1], [2].)

---

How does efficacy and steroid-sparing translate into commercial durability?

For an investment view, the commercial question is whether clinical outcomes justify switching from standard-of-care steroids and induction regimens, and whether those outcomes hold through the typical real-world patterns: delayed starts, variable adherence, and co-morbidity.

Outcome anchor used by formulary and payer bodies

Across the avacopan evidence base, the value proposition has been tied to:

• AAV disease control (induction and maintenance)
• Reduced cumulative corticosteroid exposure
• Comparable or improved safety versus steroid-regimens within trial structures.

These elements matter because steroid reduction typically converts into:

• reduced steroid-related adverse events and downstream costs
• better physician comfort, which can shorten the time to prescribing

(Clinical program context is anchored by regulatory assessments; see sources [1], [2].)

Investment translation

• Durability driver: if providers treat avacopan as “standard induction backbone,” use can persist even as other therapies compete for access.
• Erosion driver: if payer contracting forces narrow use criteria, volume can compress even if outcomes remain strong.

---

What are the commercial fundamentals you can model right now?

Because the scenario requires an investment-ready framing, the correct approach is to build a fundamentals model around the levers below: market access mechanics, contracting intensity, and channel mix. The highest-impact items are gross-to-net, utilization curve shape, and persistence (repeat cycles).

Revenue engine model (structure)

1. Treated patient volume in labeled AAV
   • incident AAV and diagnosed relapses within the treated population
   • share captured from standard-of-care regimens
2. Net price per course
   • list price minus rebates, patient assistance, and payer discounts
3. Course length and switching rate
   • duration and adherence drive dose-based revenue
   • switching from steroids or from competing biologics influences share

What to watch in quarterly disclosures and payer commentary

• Gross-to-net trend: COGS is typically not the binding constraint; contracting is.
• Mix shift: any movement between first-time AAV and relapsed/refractory populations.
• Start rate: the speed from diagnosis to treatment initiation.

---

Who are the competitive threats and how do they pressure share?

AAV treatment is an established therapeutic area with multiple entrants and evolving standards. Avacopan’s specific differentiator is C5aR blockade with steroid-sparing.

Competitive vectors that can compress utilization

• Other steroid-sparing or steroid-minimization strategies that achieve comparable safety profiles.
• Biologic and immunosuppressive regimens that compete for induction and maintenance windows.
• Formulary tightening after initial uptake if payers perceive marginal benefit for subgroups.

Investment implication

Avacopan is most exposed where payers can segment access by:

• disease severity
• renal involvement
• prior therapy history
• concomitant immunosuppression

---

What is the regulatory and competitive setting across major markets?

Avacopan is approved by both FDA and EMA, which supports multi-market revenue potential, but also increases the likelihood of:

• quicker payer action following label-driven expansion
• faster benchmarking by competitors in pricing and contracting

Regulatory anchor

• FDA approval in 2021 for AAV indication(s) (see sources [1]).
• EMA approval in 2021 (see sources [2]).

This matters for investment timing: the first full commercialization window typically reveals the net price and persistence realities that drive valuation.

---

How should investors scenario-plan: base, bull, and bear?

The investment scenario should reflect how AAV volumes, net pricing, and persistence behave across three paths: stable uptake (base), faster capture (bull), or payer-led restriction (bear).

Base case (model assumption set)

• Continued growth from standard-of-care conversion
• Net price stability with ongoing gross-to-net but no step-function deterioration
• Persistence remains tied to induction cycles with modest relapsed reuse

Bull case (what has to happen)

• Broader real-world adoption across more AAV subgroups
• Meaningful payer inclusion without restrictive criteria
• Durable steroid-sparing adoption sustains physician preference

Bear case (what breaks)

• Payer restriction narrows eligible use and reduces course access
• Contracting forces net price compression faster than utilization growth
• Competitive displacement in induction windows reduces share

The scenario architecture is consistent with how specialty pharma volumes and pricing usually behave in AAV-type rare immunology markets: share growth depends more on access and contracting than on pure trial efficacy.

---

What life-cycle levers could extend the investment horizon?

For C5aR antagonism, life-cycle extension usually comes from:

• additional line-of-therapy positioning within AAV
• longer-term outcomes and supportive data that strengthen payers’ willingness-to-pay
• combination or sequencing strategies that improve tolerability or adherence

The investment question is whether label expansion or evidence expansion broadens addressable use without triggering payer segmentation that undermines pricing.

---

What are the key diligence checkpoints for investors evaluating TAVNEOS?

Commercial diligence (highest ROI)

• Net pricing stability: trend net revenue growth versus implied demand growth.
• Access depth: whether payers cover broad AAV categories or only narrow severity.
• Persistence/cycle economics: the average number of treated courses per patient cohort.
• Physician adoption: share shifts in center-based specialty prescribing.

Regulatory diligence

• any post-approval updates to labeling that change the treated population
• any safety signal changes that alter payer comfort

---

Key Takeaways

• TAVNEOS (avacopan) is an oral C5aR antagonist used in ANCA-associated vasculitis, with commercial value anchored in steroid-sparing and AAV disease control.
• Investment fundamentals should be modeled around treated volume, gross-to-net, and course persistence, not only trial outcomes.
• The scenario risk is primarily payer access and contracting plus competitive substitution for AAV induction and maintenance windows.
• Regulatory approval in 2021 across FDA and EMA supports multi-market planning, with the next phase dependent on evidence strength translating into durable reimbursement.

---

FAQs

1) What is TAVNEOS used for?

TAVNEOS (avacopan) is used to treat ANCA-associated vasculitis (AAV) in approved indications under its FDA and EMA labels.

2) How does avacopan work?

Avacopan is an oral C5a receptor (C5aR) antagonist that targets inflammatory signaling relevant to AAV.

3) What is the main commercial differentiator?

The commercial differentiator is steroid-sparing while maintaining AAV disease control, which affects payer and physician willingness to adopt.

4) What poses the biggest investment downside?

The biggest downside is payer-led access restriction and net price compression, which can outpace utilization growth even if efficacy remains strong.

5) Which markets matter first for commercialization?

The core initial commercial footprint is typically built around major regulatory geographies where TAVNEOS is approved, including the US (FDA) and Europe (EMA).

---

References

[1] U.S. Food and Drug Administration. (2021). FDA approves avacopan for ANCA-associated vasculitis. FDA News Release.
[2] European Medicines Agency. (2021). EMA recommends approval of avacopan for ANCA-associated vasculitis. EMA Press Release.